Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep;58(3):427-32.
doi: 10.1016/j.eururo.2010.05.040. Epub 2010 Jun 4.

Homogeneous prostate cancer mortality in the Nordic countries over four decades

Affiliations

Homogeneous prostate cancer mortality in the Nordic countries over four decades

Mara S Meyer et al. Eur Urol. 2010 Sep.

Abstract

Background: Incidence of prostate cancer (PCa) has greatly increased in the Nordic region over the past two decades, following the advent of prostate-specific antigen (PSA) screening. Consequently, interpreting temporal trends in PCa has become difficult, and the impact of changes in exposure to causal factors is uncertain.

Objective: To reveal geographic differences and temporal trends in PCa in the Nordic countries. Because the recorded incidence of PCa has been profoundly influenced by PSA screening, we focused our analyses primarily on PCa mortality.

Design, setting, and participants: We analyzed national PCa incidence and mortality data from Denmark, Finland, Norway, and Sweden from 1965 to 2006 using the PC-NORDCAN software program and the online NORDCAN database.

Measurements: Cumulative incidence and cumulative mortality from PCa were calculated for selected calendar years during four decades, along with age-standardized mortality rates. Incidence data in NORDCAN come from individual countries' cancer registries, and mortality data come from national mortality registries.

Results and limitations: From 1965 to 2006, 172 613 deaths from PCa were reported in the four Nordic countries. A substantial rise in incidence was observed across the region, with some geographic variation, since the late 1980s. In contrast, both disease-specific mortality rates and cumulative risk of PCa mortality lacked consistent temporal trends over the same period. Cumulative mortality from PCa ranged between 3.5% and 7.5% in the region over four decades, whereas cumulative incidence jumped from about 9% to >20%. Mortality has remained fairly constant among the countries, with a minimally lower risk in Finland.

Conclusions: Unlike most malignancies, the occurrence of lethal PCa showed minimal geographic variation and lacked consistent temporal trends over four decades. These findings may guide our search for important causes of PCa, a malignancy with etiology that is still largely unknown.

PubMed Disclaimer

Conflict of interest statement

Financial disclosures: I certify that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/ affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

Figures

Fig. 1
Fig. 1
Cumulative risk of prostate cancer mortality among men in the Nordic countries, NORDCAN 1965–2006. Reproduced with permission of the Association of the Nordic Cancer Registries [3].
Fig. 2
Fig. 2
Cumulative risk of prostate cancer incidence in Finland, Denmark, Norway, and Sweden by age group, NORDCAN 1965–2006.
Fig. 3
Fig. 3
Cumulative risk of prostate cancer mortality in Finland, Denmark, Norway, and Sweden by age group, NORDCAN 1965–2006.
Fig. 4
Fig. 4
Age-standardized prostate cancer mortality rates (per 100 000) in four Nordic countries, NORDCAN 1965–2006. Reproduced with permission of the Association of the Nordic Cancer Registries [3]. ASR = age-standardized rate.

References

    1. Surveillance Epidemiology and End Results. Previous Version: SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; 2009. Web site. http://seer.cancer.gov/csr/1975_2006/
    1. Kvale R, Auvinen A, Adami HO, et al. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst. 2007;99:1881–7. - PubMed
    1. NORDCAN—on the web. Version 3.6. Association of the Nordic Cancer Registries; Apr, 2010. Web site. http://www.ancr.nu.
    1. Adolfsson J, Garmo H, Varenhorst E, et al. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol. 2007;41:456–77. - PubMed
    1. Mucci L, Signorello L, Adami HO. Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, editors. Textbook of Cancer Epidemiology. 2. Oxford, UK: Oxford University Press; 2008. pp. 517–54.